Claims for Patent: 10,259,791
✉ Email this page to a colleague
Summary for Patent: 10,259,791
| Title: | High-purity quinoline derivative and method for manufacturing same |
| Abstract: | Provided is a compound represented by formula (IV) or a salt thereof, wherein the content of the compound represented by formula (I) is 350 ppm by mass or less. |
| Inventor(s): | Taiju Nakamura, Taichi Abe, Yusuke Miyashita, Hirofumi Kuroda, Yusuke Ayata, Atsushi Akao |
| Assignee: | Eisai R&D Management Co Ltd |
| Application Number: | US15/503,108 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 10,259,791 |
| Patent Claims: |
1. A methanesulfonate salt of a compound represented by formula (IV), wherein the content of a compound represented by formula (A-1) is 60 ppm by mass or less 2. The methanesulfonate salt of a compound represented by formula (IV) according to claim 1, wherein the content of a compound represented by formula (I) is 183 ppm by mass or less, and the content of a compound represented by formula (A-1) is 60 ppm by mass or less 3. A method for producing a compound represented by formula (IV) or a salt thereof, comprising: a step B of allowing a compound represented by formula (I) or a salt thereof to react with a compound represented by formula (II-A) or formula (II-B) wherein R1 is a C1-6 alkyl group, a C2-6 alkenyl group, a C6-10 aryl group, or a C7-11 aralkyl group, wherein the C1-6 alkyl group or the C2-6 alkenyl group may have one to three substituents that may be the same or different and are selected from the group consisting of a halogen atom and a methoxy group, and wherein the C6-10 aryl group or the C7-11 aralkyl group may have one to three substituents that may be the same or different and are selected from the group consisting of a halogen atom, a methyl group, a methoxy group, and a nitro group; and X is a halogen atom, in the presence of a base to thereby obtain a compound represented by formula (III) wherein R1 is the same group as above, and a step C of, after allowing the compound represented by formula (III) obtained in the step B to react without isolation with cyclopropylamine, precipitating and isolating a compound represented by formula (IV) or a salt thereof by introducing a hydrous organic solvent to a reaction solution. 4. The method according to claim 3, comprising: a step A of, after allowing a compound represented by formula (A-1) to react with a compound represented by formula (A-2) or a salt thereof in the presence of a base, precipitating and isolating a compound presented by formula (I) or a salt thereof from a reaction solution by introducing a hydrous organic solvent to the reaction solution, a step B of allowing the compound represented by formula (I) or a salt thereof obtained in the step A to react with a compound represented by formula (II-A) or formula (II-B) wherein R1 is a C1-6 alkyl group, a C2-6 alkenyl group, a C6-10 aryl group, or a C7-11 aralkyl group, wherein the C1-6 alkyl group or the C2-6 alkenyl group may have one to three substituents that may be the same or different and are selected from the group consisting of a halogen atom and a methoxy group, and wherein the C6-10 aryl group or the C7-11 aralkyl group may have one to three substituents that may be the same or different and are selected from the group consisting of a halogen atom, a methyl group, a methoxy group, and a nitro group; and X is a halogen atom, in the presence of a base to thereby obtain a compound represented by formula (III) wherein R1 is the same group as above, and a step C of, after allowing the compound represented by formula (III) obtained in the step B to react without isolation with cyclopropylamine, precipitating and isolating a compound represented by formula (IV) or a salt thereof by introducing a hydrous organic solvent to a reaction solution. 5. The method according to claim 3, further comprising a step D of converting the compound represented by formula (IV) obtained in the step C into a salt of the compound represented by formula (IV). 6. The method according to claim 5, wherein the salt obtained in the step D is a methanesulfonate. 7. The method according to claim 3, wherein the step B is a step of allowing the compound represented by formula (I) or a salt thereof to react with the compound represented by formula (II-A) wherein R1 is a C6-10 aryl group that may have one to three substituents that may be the same or different and are selected from the group consisting of a halogen atom, a methyl group, a methoxy group, and a nitro group; and X is a halogen atom, in the presence of a base to thereby obtain a compound represented by formula (III) wherein R1 is the same group as above. 8. The method according to claim 3, wherein the compound represented by formula (II-A) is phenyl chloroformate. 9. The methanesulfonate salt of a compound represented by formula (IV) according to claim 3, wherein the content of the methanesulfonate salt of a compound represented by formula (IV) is 98.0% by mass or more 10. The methanesulfonate salt of a compound represented by formula (IV) according to claim 2, wherein the content of the methanesulfonate salt of a compound represented by formula (IV) is 98.0% by mass or more 11. The methanesulfonate salt of a compound represented by formula (IV) according to claim 3, wherein the content of the compound represented by formula (A-1) is determined by HPLC. 12. The methanesulfonate salt of a compound represented by formula (IV) according to claim 2, wherein the content of the compound represented by formula (I) and the content of the compound represented by formula (A-1) are measured by HPLC. |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
